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diseases and is highly prevalent in patients with pacemakers (PMs).
OBJECTIVE To validate a transthoracic impedance sensor with an
advanced algorithm (sleep apnea monitoring) for identifying severe SA.
METHODS Patients with indications for PM (VVI/DDD) were
enrolled regardless of symptoms suggesting SA. Severe SA diag-
nosis was acknowledged when the full polysomnography gave an
apnea-hypopnea index (PSG-AHI) of Z30 events/h. The PSG-AHI
was compared with the respiratory disturbance index evaluated by
the SAM algorithm (SAM-RDI) compiled from the device during the
same diagnosis night, and the performance of the device and the
SAM algorithm was calculated to identify patients with severe SA.
The agreement between methods was assessed by using Bland and
Altman statistics.
RESULTS Forty patients (mean age 73.8 19.1 years; 67.5% men;
body mass index 27.7  4.4 kg/m2) were included. Severe SA was
diagnosed by PSG in 56% of the patients. We did not retrieve SAM-
RDI data in 14% of the patients. An optimal cutoff value for the
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(95% conﬁdence interval [CI] 65.3%–98.6%), a positive predictive
value of 88.9% (95% CI 65.3%–98.6%), and a speciﬁcity of 84.6%
(95% CI 54.6%–98.1%) (n ¼ 31). The Bland-Altman limits of
agreement for PSG-AHI (in events per hour) were [14.1 to 32.4].
CONCLUSION The results suggest that an advanced algorithm
using PM transthoracic impedance could be used to identify SA in
patients with PMs outside the clinic or at home.
KEYWORDS Bradycardia; Pacemaker; Minute ventilation; Sleep
apnea; Sleep apnea diagnosis
ABBREVIATIONS CI ¼ conﬁdence interval; NPV ¼ negative
predictive value; PM ¼ pacemaker; PPV ¼ positive predictive
value; PSG¼ polysomnography; PSG-AHI¼ apnea-hypopnea index
evaluated by polysomnography; SA ¼ sleep apnea; SAM ¼ sleep
apnea monitoring; SAM-RDI ¼ respiratory disturbance index
evaluated by the sleep apnea monitoring algorithm
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Sleep apnea (SA) is common in middle-age general pop-
ulation, and its prevalence increases up to 20% above 70
years.1 A great number of clinical prospective cohorts and
epidemiological studies demonstrated that obstructive SA
constitutes an independent risk factor to cardiovascular
morbidities and mortality. Obstructive SA is now implicated
as a risk factor for hypertension, stroke, coronary artery
disease, congestive heart failure, and arrhythmias.2,3 SA has
been proposed to be causally related to arrhythmias and
sudden cardiac death.4,5 A high prevalence of SA in patients
with cardiac implants6 requires a speciﬁc diagnosis strategyhttp://dx.doi.org/10.1016/j.hrthm.2014.02.011
843Defaye et al Validation of the Sleep Apnea Monitoring Algorithmbecause SA recognition might represent a potential thera-
peutic target for reducing occurrence and recurrence of
arrhythmia.
Patients referred for SA diagnosis usually present with
associated symptoms such as snoring, apneas, and/or exces-
sive daytime sleepiness. Patients with cardiovascular disor-
ders are frequently nonsleepy and less symptomatic.6,7
Appropriate screening/diagnosis tools are lacking or have
not been validated in these at-risk populations. Up to now,
polysomnography (PSG) remains the “gold standard” to
diagnose SA but is challenged by waiting lists of sleep
laboratories and high related costs.8 Rate-responsive pace-
makers (PMs) use minute ventilation sensors to adjust heart
rate and have demonstrated the capability to detect breathing
variations by using transthoracic impedance measurements.
Previous studies have suggested to use this information as a
screening tool for detecting SA.9–11 The primary goal of the
DREAM study was to assess the accuracy of a novel
advanced algorithm using transthoracic impedance and
minute ventilation (sleep apnea monitoring [SAM] algo-
rithm) to detect severe SA in unselected population of
bradycardia patients with newly implanted PMs. The vali-
dation of the SAM algorithm was performed against full
sleep studies scored in an expert core laboratory. The secon-
dary goal was to determine the prevalence of moderate to
severe SA in our population.Methods
Study design
The DREAM study (Clinicaltrials.gov identiﬁer:
NCT01537718) is a European prospective multicenter study
in new patients who were eligible for the implantation of a
single- or a dual‐chamber PM according to the available
guidelines.12 Patients were consecutively included, regard-
less of symptoms suggesting SA. The study has been
approved by ethics committees and regulatory health author-
ities of different countries involved in the study. All patients
signed an informed consent form. The study was conducted
in accordance with the Declaration of Helsinki, Good
Clinical Practice, and all applicable laws and regulations.
All adverse events occurring during the course of the study
were reported, followed up, and reviewed to identify any
potential relationship between the PM device and safety.Study population and follow-up
Patients were implanted with a single- or a dual-chamber PM
(REPLY 200 SR or DR, Sorin CRM SAS, Clamart, France).
The choice of the right atrial (when applicable) and right
ventricular leads was left at investigators’ discretion. Bipolar
leads were not mandatory, except when a single-chamber
device was implanted. Patients were followed up for 3
months. Three visits were scheduled: at prehospital dis-
charge and 1 month and 3 months after implantation. During
these visits and at any unscheduled visits, the cardiologist
performed routine checks of the PM and lead(s).Between 1-month and 3-month visits, patients spent 1
night at the Sleep Laboratory of the University Hospital they
had been admitted to undergo PSG. Polysomnography record-
ings were standardized between the different participating
centers and included measurements of electroencephalograms,
chin electromyogram, electrocardiogram, electrooculogram,
pulse oximetry, nasal pressure, and thoracic and abdominal
movements. The central reading of PSGs was done in an
expert core laboratory (University Hospital, Grenoble, France)
according to the AASM scoring rules.13
The PM device data obtained using the SAM algorithm
(time window 0:00–5:00) were downloaded in the morning
after PSG.
Objectives and study outcomes
The main objective of the study was to evaluate the
performance of the SAM algorithm in comparison to PSG
by using the following 2 approaches:1. An event-based approach, which assessed the perform-
ance of the SAM algorithm toward the detection of
abnormal respiratory events, as determined from inves-
tigators’ interpretation of PSG;2. An index-based approach, which assessed the perform-
ance of the SAM algorithm toward the diagnosis of SA
severity, as determined from the apnea-hypopnea index
derived from PSG scoring. In this approach, the apnea-
hypopnea index evaluated by PSG (PSG-AHI) and the
respiration disturbance index evaluated by the SAM
algorithm (SAM-RDI) were compared and an agreement
between the methods was assessed.
The prevalence of SA in the study population was
determined by using the PSG-AHI.
Events detection by PSG and device-based feature
(SAM algorithm)
PSG scoring was the responsibility of a central core labo-
ratory (JLP, Sleep Laboratory of the CHU, Grenoble, France).
The central core laboratory took care of the quality of tracings
and avoided between centers variability in AHIs evaluation.
The central core laboratory was blinded for the SAM-RDI
results. PSG measurements were scored according to current
guidelines.13 The PSG-AHI was deﬁned as the hourly average
number of abnormal breathing events during sleep. The
severity of SA was rated by using the following deﬁnitions:
PSG-AHIo 15 events/h: no or mild SA; 15 events/hr PSG-
AHIo 30 events/h: moderate SA; PSG-AHIZ 30 events/h:
severe SA.
A previous version of the SAM algorithm has been
described previously.11 Brieﬂy, a PM sensor derives minute
ventilation from transthoracic impedance measurements. A
current pulse was injected between the PM can and one of
the pacing electrodes. Voltage (proportional to impedance)
was measured between the can and another electrode located
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varies with respiratory movements, body posture, and
cardiac contractions. Only relative impedance was consid-
ered; therefore, the sensor measurements were independent
from the lead and the can position. An appropriate ﬁltering
(low-pass ﬁlter at 0.5 Hz and a band-pass ﬁlter at 0.05–0.5
Hz) was applied on the transthoracic impedance signal. Each
respiratory cycle’s amplitude and period were measured
from the impedance signal; and the minute ventilation value
and the index were calculated as the ratio, or average of the
ratio, of amplitude and period.
The SAM algorithm detects the following events: apnea
(absence of a signiﬁcant respiratory cycle for410 seconds)
and marked hypopnea (sustained,410 seconds, reduction of
the respiratory amplitude by at least 50% compared to the
mean minute ventilation of preceding validated respiratory
cycles). After PM interrogation, a respiratory disturbance
index evaluated by the SAM algorithm (SAM-RDI), corre-
sponding to the mean number of detected events per hour of
the estimated sleep, was automatically computed.
Compared to the previous version of the algorithm,
respiratory cycles with unexpected baseline motion (poten-
tially due to patient’s changes in body position, yawning, or
coughing) and cycles presenting an abnormal signal-to-noise
ratio were tracked and were excluded from the analysis.
Another signiﬁcant improvement is the management of
repeated ﬂow cycles with artifacts: in the case of frequentFigure 1 Nasal pressure measurements during polysomnography (PSG) and
impedance from the minute ventilation sensor.A: Two typical apneas are framed. A
in the peak signal excursion by Z90% of pre-event baseline. Note the concurr
pacemaker. B: Hypopnea events are framed. Hypopneas in adults are scored when
pressure. Note the simultaneous reduction of the amplitude of the thoracic impedacycle exclusions (more than 4 cycles excluded over the last
16) within or preceding the suspicion of an apnea or
hypopnea, the detection of the event was discarded from
the ﬁnal SAM-RDI. An analysis of the total number of
excluded cycles was performed at the end of the night, and
no SAM-RDI was provided when excluded cycles exceeded
400 cycles/h overnight. The signal processed by the SAM
algorithm was then synchronized with the recorded PSG
tracing (Figure 1).
For the event-based approach, the ﬁrst 40 events recorded
by PSG for each patient (presenting at least 40 PSG events)
were matched with the events recorded by the device.
For the index-based approach, performances of the SAM
algorithms were assessed on patients with implanted devices
with appropriate data for PSG-AHI and SAM-RDI calcu-
lation, that is, completed PSG and valid data from PSG and
the SAM algorithm, respectively, during the evaluation
night.Statistical analysis
Study data were reported in the case report forms by the
investigators, and device outputs were extracted on Excel
ﬁles. A database was built-up on Oracle Clinical Database
(Clinical Release 4.6), and the global study database was
frozen on June 4, 2013, and exported to SAS software.
Quantitative variables were expressed as mean  SD.corresponding sleep apnea monitoring (SAM) recordings of transthoracic
pneas are identiﬁed clearly on the nasal pressure signal during PSG as a drop
ent reduction of the amplitude of the thoracic impedance signal from the
the peak signal excursions drop byZ30% of pre-event baseline using nasal
nce signal from the pacemaker.
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and percentage.
The occurrence and severity of SA were evaluated in
patients with implanted devices who completed PSG. The
device performance for severe SA identiﬁcation was eval-
uated by the area under the receiver operator characteristic
curve (Wald method) at different RDI cutoffs and compared
with the area under the random guess line by using a χ2 test.
The optimal cutoff point (SAM-RDI) to discriminate the 2
populations (patients with severe and nonsevere SA) was
determined by the best trade-off between sensitivity and
speciﬁcity. Conﬁdence intervals (CIs) were calculated for
sensitivity, speciﬁcity, negative predictive value (NPV), and
positive predictive value (PPV) by using the Clopper-
Pearson exact method. An agreement between the 2 indexes
was evaluated by using a scatter plot and Bland and Altman
statistics.14 All statistical analyses were performed with SAS
software, version 9.2 (SAS Institute, Cary, NC).Results
Study population and study ﬂow
A total of 40 patients were enrolled in the DREAM study
between March 13, 2012, and July 25, 2012, in 5 centers in
France and Spain. Their mean age was 73.8  19.1 years,
and mean body mass index was 27.7  4.4 kg/m2; most
patients were men (67.5%). Detailed demographic character-
istics and implantation statistics are summarized in Table 1.
Three patients (7.5%) withdrew their consent before
undergoing PSG, and 1 patient (2.5%) experienced an acute
cardiac failure during his examination through PSG. Con-
sequently, 36 patients (90%) completed their overnight PSGTable 1 Demographic characteristics (N ¼ 40)
Age (y) 73.8  10.1
Sex: male 27 (67.5)
Body mass index (kg/m2) 27.7  4.4
Indication for implantation
AVB III/II 20 (50.0)
Syncope 6 (15.0)
Brady-tachy syndrome 5 (12.5)
Sinus node dysfunction 9 (22.5)
Atrial rhythm disorders at inclusion
Paroxysmal atrial ﬁbrillation 8 (20.5)
Persistent/permanent atrial ﬁbrillation 6 (15.4)
Underlying cardiac diseases
Coronary artery disease 6 (15.0)
Valvular heart disease 2 (5.0)
Cardiomyopathy 9 (22.5)
Hypertension 25 (62.5)
Cardiac failure 16 (40.0)
Other comorbidities
Diabetes 5 (12.5)
Current smoker 8 (20.0)
Implanted device
REPLY 200 single chamber 10 (25.0)
REPLY 200 dual chamber 30 (75.0)
Initial implant 33 (88.5)
Replacement 7 (17.5)
Values are presented as mean  SD or as n (%). AVB III/II: atrio-
ventricular block 3rd degree/2nd degree.recordings and were analyzed for SA diagnosis. The SAM-RDI
was not available for 5 (14%) patients owing to signal artifacts
for the study night. Therefore, 31 patients were analyzed for
performances of SAM algorithms.
SA prevalence
A wide range of the PSG-AHI values between 4 and 82
events/h were obtained from PSG performed overnight, and
the diagnosis of moderate to severe SA (PSG-AHI 4 15
events/h) was made in 78% of our unselected population of
patients with PMs (n ¼ 36), with 56% receiving a diagnosis
of severe SA (PSG-AHI 4 30 events/h).
Performance of the SAM algorithm
Event-based approach
The event-by-event comparison between PSG and SAM data
(1802 abnormal respiratory events studied) provided a
sensitivity of 60.4% (95% CI 57.6%–63.2%) and a PPV of
50.6% (95% CI 48.0%–53.3%).
Index-based approach
In the index-based approach, the SAM-RDI ranged from 0.0
to 70.5 events/h. The area under the receiver operator
characteristic curve was 0.91 (95% CI 0.80–1.00; P o
.001; Figure 2). The optimal SAM-RDI cutoff value for
detecting patients with severe SA (PSG-AHI4 30 events/h)
was 20 events/h. With this optimal cutoff value (SAM-RDI
4 20 events/h), 16 of 18 patients who received the diagnosis
of severe SA through PSG were accurately detected by the
SAM algorithm (sensitivity 88.9%, 95% CI 65.3%–98.6%;
speciﬁcity 84.6%, 95% CI 54.6%–98.1%; PPV 88.9%, 95%
CI 65.3%–98.6%; NPV 84.6%, 95% CI 54.6%–98.1%).
A scatter plot (Figure 3) and Bland and Altman statistics
(Figure 4) indicated a good agreement between the 2
methods. The difference (systematic error or bias) between
the PSG-AHI and the SAM-RDI was 9.2 events/h. In
patients with severe SA (SAM-RDI Z 20 events/h), the
mean difference was 14.3 events/h.
Discussion
Main ﬁndings
In our unselected population of patients with PMs, we found
a prevalence of 78% in moderate to severe SA and 56% in
severe SA. An optimal cutoff of 20 events/h for the SAM-
RDI value was validated to identify severe SA with a
sensitivity of 88.9% (95% CI 65.3%–98.6%), a PPV of
88.9% (95% CI 65.3%–98.6%), and a speciﬁcity of 84.6%
(95% CI 54.6%–98.1%).
Prevalence of SA in patients with cardiac implants
In a population of patients newly implanted for symptomatic
sinus dysfunction, permanent atrioventricular block, or severe
heart failure, the prevalence rate of SA was up to 59%, with
27% of the patients suffering from severe disease.6 The
prevalence of symptoms of disordered breathing was 32.3%
in a population implanted for bradyarrhythmia.15 In the
Figure 2 Receiver operator characteristic curve for the detection of severe sleep apnea (deﬁned as PSG-AHI4 30 events/h). The sensitivity is plotted against
(1  speciﬁcity) at different SAM-RDI cutoffs (in red). The smoothed curve is shown in black. Statistics are provided with the optimal SAM-RDI cutoff of 20
events/h found to provide the best trade-off between sensitivity and speciﬁcity. AUC ¼ area under the curve; PSG-AHI ¼ apnea-hypopnea index evaluated by
polysomnography; SAM-RDI ¼ respiratory disturbance index evaluated by the sleep apnea monitoring algorithm.
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lence rate of 78% for the moderate to severe spectrum of the
disease, which included 56% of the patients exhibiting severe
SA. This result is consistent with the study of Shalaby et al,10
which gave prevalence rates of 67% and 53%, respectively, in
a population aged 69  12 years. In our DREAM study,
population was older (73.8  10.1 years) than that in the 2
studies mentioned previously (63 8 and 62.2 12.2 years),
and this certainly partially explain the highest prevalence of
SA in the DREAM cohort. The diagnosis method used by
Fietze et al15 differed signiﬁcantly from other studies, since
SA was searched by using simpliﬁed tools (MESAM IVFigure 3 Scatter plot between the respiratory disturbance index evaluated by t
evaluated by polysomnography (PSG-AHI, in events/h). PSG-AHI ¼ apnea-hypop
SAM-RDI ¼ respiratory disturbance index evaluated by the sleep apnea monitoridevice, MAP, Munich, Germany) based on heart rate, snoring
and oxygen saturation without information on sleep quality or
duration, or direct measurements of airﬂow. This diagnosis
procedure clearly underestimated hypopnea. In summary, all
available studies exhibited an undiagnosed SA rate above
50% in patients implanted with PMs. This ﬁgure has recently
been expended in patients implanted with cardioverter-
deﬁbrillators.16–18
Performance of the SAM algorithm in perspective
The index-based approach is the most clinically relevant
approach for identifying patients with severe SA. Ahe SAM algorithm (SAM-RDI, in events/h) and the apnea-hypopnea index
nea index evaluated by polysomnography; SAM ¼ sleep apnea monitoring;
ng algorithm.
Figure 4 Bland-Altman plot (y axis: difference between the PSG-AHI and the SAM-RDI; x axis: mean of the SAM-RDI and PSG-AHI), showing mean of the
differences (bias) presented with the 2SD interval. Mean ¼ 9.2  11.6; limits of agreement (2SD) ¼ [14 to 32.4]. SA ¼ sleep apnea; PSG-AHI ¼ apnea-
hypopnea index evaluated by polysomnography; SAM-RDI ¼ respiratory disturbance index evaluated by the sleep apnea monitoring algorithm.
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Talent PM, ELAMedical) had been studied by Defaye et al11
in patients with PMs. A cutoff RDI value of 30.6 events/h
was found to yield 75% sensitivity, 94% speciﬁcity, 75%
PPV, and 94% NPV. The advanced algorithm presented
here showed higher performances (89% sensitivity while
maintaining a high speciﬁcity). This was mainly achieved
through improved management of nonphysiological artifacts
of the minute ventilation signal. Five of 36 patients with PSG
data had no SAM-RDI provided owing to the new artifact
exclusion management. However, this signiﬁcant failure
rate corresponded to data acquired during a single night.
In clinical practice, this concern will be solved by the night
after night measurements of the SAM-RDI, which will
provide correct SA screening information for nearly all the
patients.
To our knowledge, 2 other device-based respiratory
sensor–equipped PMs have been studied for the diagnosis
of SA. Shalaby et al10 reported a good correlation between
the PM-AHI and the PSG-AHI (r ¼ .80; P o .01) and
identiﬁed patients with moderate to severe SA, with an
index-based sensitivity of 89.3%, a speciﬁcity of 66.7%, and
a PPV of 73.5%. From the individual data reported by Scharf
et al,9 we have extrapolated on the whole population a
sensitivity of 78%, a speciﬁcity of 92.3%, a PPV of 87.5%,
and an NPV of 85.7%.
These studies including our own are limited by their
relatively small sample size; evaluation in larger populations
is needed to fully validate these diagnostic tools and their
cost-effective beneﬁts. Also, further technological develop-
ments will certainly improve the reliability of the system by
allowing us to better estimate sleep duration via combined
activity sensor and algorithms.Study limitations
The evaluation of the performance presented herein was not
conducted on a training set and an evaluation data set of
patients. This can be considered as a signiﬁcant design
limitation. The DREAM study should be considered as the
ﬁrst validation step of this new technology, and further
prospective multicenter studies or registries are required.
Transthoracic impedance measurements of ventilation are
qualitative estimates of ventilation. They do not allow a
quantitative ﬂow measurement, which constitutes a limita-
tion for subtle hypopnea recognition. Also, this system does
not assess directly the severity of nocturnal hypoxia, which is
the landmark of SA. However, the duration of abnormal
respiratory events is available and reﬂects the severity of
intermittent hypoxia. Both sleep macrostructure and micro-
arousals are not detected by the device. To address this
limitation, the patient’s sleep period can be adjusted in
accordance with patient’s sleep habits (programmed between
0:00 and 5:00 in the DREAM study to ensure a high
probability of sleep during the recording period). Finally,
an interesting evolution in the development of the sensor
would be to discriminate the central from obstructive apnea
events by looking at different speciﬁc ventilatory patterns.19Clinical implications and perspectives
As the prevalence of SA is up to 65% in the different
population with indications for cardiac implants, awareness
of cardiologist should increase in this ﬁeld. More than three-
quarters (78%) of the unselected patients of the DREAM
study were diagnosed with moderate to severe SA by
using the gold standard method, that is, PSG. This new
transthoracic impedance-derived PM for severe SA
Heart Rhythm, Vol 11, No 5, Month 2014848screening/diagnosis and follow-up is now commercially
available in various implantable devices; it may improve
the management of patients in routine cardiology practice.
An ongoing registry, the Registry of Sleep Apnea Monitor-
ing and Atrial Fibrillation in Pacemaker Patients (Clinical-
trials.gov identiﬁer: NCT01922726), will provide a long-
term evaluation of the effect of this systematic SA screening
on clinical outcomes in patients with implantable cardiac
devices. The night after night measurements after implanta-
tion would help understand the evolution of severe SA,
together with different therapeutic interventions.
Conclusions
The DREAM study showed that a transthoracic impedance
sensor with an advanced algorithm, the SAM algorithm,
could be used to identify severe SA in patients with PMs.
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